CN102935116A - Pharmaceutical compositions or health care product having blood sugar reduction effect - Google Patents
Pharmaceutical compositions or health care product having blood sugar reduction effect Download PDFInfo
- Publication number
- CN102935116A CN102935116A CN2012105050968A CN201210505096A CN102935116A CN 102935116 A CN102935116 A CN 102935116A CN 2012105050968 A CN2012105050968 A CN 2012105050968A CN 201210505096 A CN201210505096 A CN 201210505096A CN 102935116 A CN102935116 A CN 102935116A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- pharmaceutical composition
- blood sugar
- xylitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a pharmaceutical composition or health care product having a blood sugar reduction effect. The pharmaceutical composition contains the following components in parts by weight: 260-520 parts of momordica charantia extract, 290-600 parts of olive extract, 230-540 parts of cinnamon extract, 150-280 parts of guava extract, 140-310 parts of tartary buckwheat extract, 20-80 parts of astaxanthin, 20-40 parts of lutein, 10-25 parts of chromium-containing yeast, and 2500-3800 parts of xylitol. After being added with auxiliary materials or carries required for preparation forming, the pharmaceutical composition disclosed by the invention can be prepared into any suitable pharmaceutical preparation acceptable clinically according to a conventional preparation method in the field. Proved by pharmacology test result, the pharmaceutical composition or health care product has good effect of reducing blood sugar, has no toxic or side effect on animals, and is safe to take.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition or health product, relate in particular to a kind of pharmaceutical composition or health product with function of blood sugar reduction, belong to hypoglycemic medicine composition or field of health care products.
Background technology
Diabetes be because insulin secretion and (or) metabolic disease take blood sugar increasing as feature that causes of effect defective, be a kind ofly to get muddled as main comprehensive chronic disease take carbohydrate metabolism.The diabetics of long-term poor blood glucose control, the various organs that can occur together, especially eye, the heart, blood vessel, kidney, nervous lesion or organ dysfunction are incomplete or depleted, cause maimed person or premature death.
In recent years, along with the raising of the socioeconomic development in countries in the world and resident living level, sickness rate and the prevalence of diabetes raise year by year, and according to the estimation of WHO, the existing diabetics about 1.75 hundred million in the whole world will reach 300,000,000 to 2025 at present.Diabetes have become " killer " who threatens human health, become the Social Events that threatens people ' s health.National governments, hygiene department and numerous medical personnels pay close attention to and pay attention to diabetes very much at present.
No matter be developed country or developing country, the sickness rate of diabetes is all increasing year by year, think that in the past diabetes are diseases of person in middle and old age, discovered in recent years, no matter in the west or China, along with increasing of child and Adolescent Obesity disease, child and teen-age diabetes, particularly the type ii diabetes number of patients also increases rapidly, has become the early stage large health problem of life.
Diabetes can cause the serious consequences such as cardiovascular and cerebrovascular disease, uremia, blind and amputation, the harm humans life security, and psychological problems, the social problem of causing thus also become increasingly conspicuous.Because also there is very big-difference in the each department medical level, the raising universal and the diabetes medical level of Diabetes Mellitus Knowledge becomes problem demanding prompt solution.Therefore, the relevant expert points out that " diabetes no longer are the diabetics personal questions, especially a global problem.”
Hypoglycemic drug has multiplely clinically, and its main mechanism is also different.The user of clinical application mostly is suffers from diabetes, and using dosage and the course for the treatment of need decide by patient's situation.
Diabetics uses medicine to mainly contain insulin, metformin class etc. now.
Insulin is mainly beta Cell of islet and is subjected to endogenous or exogenous material, such as the stimulation of glucose, lactose, ribose, arginine, glucagon etc. and a kind of proteohormone of secreting.The mechanism of action belongs to receptor tyrosine kinase mechanism.
Insulin has certain toxic and side effects, and can not use some composition allergy sufferers in the product.
The insulin blood sugar lowering is applicable to type i diabetes, type ii diabetes patient medicine hypoglycemic effect gastrointestinal disease patient, diabetes mellitus ketoacidosis, major operation front and back, gestational diabetes, the serious hepatopathy of diabetes mellitus, secondary diabetes etc.
Dosage form and comfort level: answer cold preservation in 2-8 ℃ refrigerator, can not be freezing.Using or carrying when for subsequent use: at room temperature (but 30 ℃) were deposited for 4 weeks, must abandon after 4 weeks.
Metformin is Metformin.The mechanism of action: delay glucose is absorbed by gastrointestinal, increases the utilization of periphery glucose by the sensitivity that improves insulin, and suppresses liver, the excessive gluconeogenesis of kidney.
Metformin can cause the toxic and side effects such as febris acuta, gastrointestinal reaction, lactic acidosis.
At present, many patients with diabetes mellitus sugarfree foods such as Herba bromi japonici: can allay one's hunger, as meal supplement, but not have therapeutic effect.
Hospital's nutrient diet (miscellaneous grain crops are main) can relievedly eat, but is difficult to adhere to, without hypoglycemic effect.
With respect to day by day huge suitable crowd's quantity, pharmaceutical composition or health-product market with hypolipemic function are also saturated far away.Lack and a kind ofly start with from improving this source of insulin sensitivity, significantly control sugared blood fat reducing, fundamentally solve pharmaceutical composition or the health product of diabetes patient's trouble and worry effect.
Diabetic complication is directly related with different blood glucose levels, so diabetics is proposed always and has more meals a day but less food at each to disperse nutrient load.
Pharmaceutical composition or health product that the present invention has effect of lowering blood sugar extract the effective ingredient that is rich in blood sugar lowering control sugar from multiple natural plants, the activity that suppresses glycosidase in the intestinal, accelerate glucose and in blood, be transported to histiocyte, fully reduce giving birth to the sugar effect and keeping function of intestinal canal of food, reduce post-prandial glycemia, meet international up-to-date healthy trend.
The present invention has the pharmaceutical composition of effect of lowering blood sugar or the effect that health caring product prescription has more control sugar, blood sugar lowering, and hyperglycemia population life-time service control sugar effect is more obvious, and blood sugar reducing function is more reliable.
The present invention has pharmaceutical composition or health product 100% pure natural of effect of lowering blood sugar, green non-pollution, without any side effects, steady blood sugar level in the control agent, reduce hyperglycemia, and can not cause hypoglycemic reaction, and be fit to the diabetics life-time service, can not produce dependency and drug resistance.
Summary of the invention
The object of the invention provides a kind of pharmaceutical composition or health product with effect of lowering blood sugar, and estimates the function of blood sugar reduction of this hypoglycemic medicine composition or health product by zoopery.
Another object of the present invention provides the preparation method of this pharmaceutical composition or health product.
The present invention seeks to be achieved through the following technical solutions.
The object of the invention provides a kind of pharmaceutical composition or health product with effect of lowering blood sugar, and this pharmaceutical composition mainly is comprised of each component of following weight portion: Fructus Momordicae charantiae extract 260-520 part, Fructus Canrii Albi extract 290-600 part, Cortex Cinnamomi extract 230-540 part, guava extract 150-280 part, Radix Et Rhizoma Fagopyri Tatarici extract 140-310 part, astaxanthin 20-80 part, phylloxanthin 20-40 part, contain chromium yeast 10-25 part, xylitol 2500-3800 part.
In order to reach better therapeutic effect, preferably, the mass parts of each component is: Fructus Momordicae charantiae extract 320-440 part, Fructus Canrii Albi extract 400-500 part, Cortex Cinnamomi extract 340-440 part, guava extract 200-250 part, Radix Et Rhizoma Fagopyri Tatarici extract 200-250 part, astaxanthin 40-65 part, phylloxanthin 25-35 part, contain chromium yeast 13-21 part, xylitol 2800-3300 part.
Preferred, the mass parts of each component is: 380 parts of Fructus Momordicae charantiae extracts, 450 parts of Fructus Canrii Albi extracts, 380 parts of Cortex Cinnamomi extracts, 245 parts of guava extracts, 220 parts of Radix Et Rhizoma Fagopyri Tatarici extract, 50 parts of astaxanthins, 33 parts of phylloxanthins, contain 17 parts of chromium yeasts, 3000 parts of xylitol.
" diabetes " are the diseases of the easy overheap of glucose in a kind of blood, and domestic to its symptom so-called " hyperglycemia ", diabetes are divided the diabetes of type i diabetes, type ii diabetes, gestational diabetes and other specific types.In diabetics, the shared ratio of type ii diabetes is about 95%, and type ii diabetes is adult's morbidity type diabetes, how falls ill after 35-40 year, accounts for diabetics more than 90%.The ability that produces insulin in the patient body is not to completely lose, insulin even produce too much in the patient body that has, but the action effect of insulin has a greatly reduced quality, so the insulin in the patient body is a kind of relative shortage.
Pharmaceutical composition of the present invention or health product based on medical science to hyperglycemia disease research on mechanism and Therapeutic Principle thereof, simultaneously according to the pharmaceutical research achievement, adopt vanguard technology, blood sugar lowering, the blood fat reducing factor that success is extracted from natural plants, but the minimizing of establishment alpha-glucosidase activity and insulin secretion is from source control blood glucose and steady decrease cholesterol and monoglyceride.According to the theory of medicine prescription, be prepared from according to certain weight proportion.
Insulin in the hyperglycemia patient body is a kind of relative shortage, and the easy overheap of the glucose in the blood finally causes hyperglycemia.
In to diabetes " marathon " war, except Drug therapy and exercise therapy, " nutrition treatment " is the most basic measures for the treatment of all kinds diabetes.Diabetics will adopt and can guarantee that the nutrient formulation that nutrition can suppress again hyperglycemia just can effectively treat.
Diabetic complication is directly related with different blood glucose levels, so diabetics is proposed always and has more meals a day but less food at each to disperse nutrient load.Pharmaceutical composition of the present invention or health product can carry out the treatment of special meals to the diabetes patient, reach a lot of medicines effect that is beyond one's reach, and regulate or correct the metabolic imbalance in the diabetes human body.
Pharmaceutical composition of the present invention or health product have mainly been prepared burden: Fructus Momordicae charantiae extract, Fructus Canrii Albi extract, Cortex Cinnamomi extract, guava extract, Radix Et Rhizoma Fagopyri Tatarici extract, astaxanthin, phylloxanthin, contain chromium yeast, xylitol.Prescription is unique, effect is remarkable, according to diabetes patient's pathogeny, carries out specific aim adjusting, systematicness conditioning, and the tonification combination has obvious blood sugar reducing function.
Type ii diabetes is polygenic inheritance factor and the coefficient complex disease of environmental factors.β emiocytosis defective and insulin resistant are two principal elements in the pathogenesis.
Cortex Cinnamomi extract: the pharmacological Mechanism of Cortex Cinnamomi blood sugar reducing function mainly is by protection, stimulates beta Cell of islet to increase the content of serum insulin; increase the sensitivity of insulin; improve the insulin resistant ability; remove free radical; anti peroxidation of lipid; promote insulin secretion, increase the content of serum insulin.
Fructus Momordicae charantiae extract: the test of oral anti-sugar amount shows that momordica saponins can make impaired beta Cell of islet recover normal secretory function.
The hepatic glycogen test shows: momordica saponins all increases to some extent to the hepatic glycogen of normal and diabetic mice, shows that momordica saponins may be by stimulating hepatic glycogen to synthesize to play the blood sugar lowering effect.
Radix Et Rhizoma Fagopyri Tatarici extract: Radix Et Rhizoma Fagopyri Tatarici flavone to normal mouse blood sugar without reducing effect, the experimental hyperglycemia mouse blood sugar there is obvious reducing effect, its carbohydrate tolerance is significantly improved, glycated protein is also obviously reduced, can promote hepatic glycogen synthetic, hydrocortisone be brought out insulin resistance be improved effect.Its hypoglycemic approach may be by suppressing glycosidase, peroxide activator body multiplication agent activated form receptor y and α and realize.Radix Et Rhizoma Fagopyri Tatarici extract has obvious inhibitory action to the activity of alpha-glucosidase, and inhibition degree and acarbose are suitable.Radix Et Rhizoma Fagopyri Tatarici extract can reduce post-prandial glycemia, and this may be relevant with its Inhibiting α-glucosidase activity.
Guava extract: express and improve insulin secretion and improve tissue to the ability that absorbs of glucose by regulating in the diabetes human body liver carbohydrate metabolism key gene, promote hepatic glycogen synthetic, the minimizing glyconeogenesis, thus play the auxiliary hyperglycemic effect.
Fructus Canrii Albi extract: Compendium of Material Medica record: the olive fruits puckery is warm in nature, and is nontoxic, eats, boils the drink alcoholism that disappears raw; Chew juice and swallow it, control the fish fishbone; Give birth to eat, liquor can be separated all poison, the therapeutic method to keep the adverse QI flowing downwards of whetting the appetite, antidiarrheal, born fluid are ended excessive thirst, controlled throat pain; Chew pharynx juice, can separate all fishes, Trionyx sinensis Wiegmann poison.
Be rich in polyphenols in the Fructus Canarii albi, the effect of prevention disease of life-style is arranged.Olive polyphenol has the effect that suppresses alpha-glucosidase activity and blood glucose is reduced, and rapid rising of blood glucose that glucose load is caused has inhibitory action.Give olive polyphenol to the diabetic mice per os, all significantly suppress blood sugar increasing, and recover excreting insulin.The epidermal basal cell proliferation activity that can obviously recover induced Diabetic and reduce.
Diabetes patient 70% can develop into the nephropathy infringement in 5 years.Find that under study for action " oxidative stress " is the important mechanisms that diabetes cause nephropathy.
Astaxanthin: be unique material that can effectively stop the diabetic nephropathy infringement of finding up to now.Mainly be by direct protection glomerular basement membrane, stop the free radical that produces because of hyperglycemia to destroy basement membrane; In addition, can also resist the free radical of renal cells, protection glucose and phosphorus are in the normal transhipment of renal tubular cell, thereby preservation ATP and these important substance of sodium-potassium ATP enzyme guarantee that renal blood flow is unaffected, reduce albuminuretic generation.
Phylloxanthin: have the various biological functions such as antioxidation, removing free radical, enhancing immunologic function, the multiple relevant diseases such as cardiovascular disease, cancer, senile degeneration of macula are had certain prevention and improvement effect.
Trivalent chromium is one of necessary trace element of safest human body, and is many about the research of chromium to the diabetes effect, thinks that trace element chromium and diabetes are in close relations.As far back as the end of the fifties, the proposition trivalent chromiums such as Schwarz and Mertz are the center active component of glucose tolerance factor (GTF).Chromium mainly is to strengthen insulin function to glycometabolic effect.In the tissue that relies on insulin, even only have the increase of milli trace chromium, insulin function will obviously improve; The chromium Deficiency of Intake, health increases the demand of insulin.
Scarce chromium can make impaired glucose tolerance, blood insulin raise, the insulin affinity reduces, the β cellular sensitivity reduces, Insulin receptor INSR reduces, and blood glucose is too high or too low.Above-mentioned unusually can obtaining behind chromium supplement corrected
Containing chromium yeast is that yeast cells is cultivated in containing chromic culture medium, by biotransformation inorganic chromium is transformed into organic chromium, thereby improves chromium absorption rate in body, brings into play better the effect that it regulates blood glucose, blood fat reducing and cholesterol reducing.
The blood sugar lowering mechanism of xylitol may synthesize, increase Insulin receptor INSR sensitivity, promote that glucose utilizes relevant in peripheral tissues with the promotion hepatic glycogen.The intravenous injection xylitol without impact, but can stimulate the islet cells excreting insulin to the blood glucose of diabetics.
Various raw materials required for the present invention, specification all meet national medical standard, can obtain from company or manufacturer's purchase of managing Related product.
Each component in pharmaceutical composition of the present invention or the health product is pure natural plant extract, integration of edible and medicinal herbs.Edible at once after meal, also can add in the medicated porridge edible, without taboo.
Each component in pharmaceutical composition of the present invention or the health product, be prepared into any clinically acceptable suitable drugs preparation or health product according to this area or conventional formulation method, it for example can be oral formulations, wherein, described oral formulations includes but not limited to tablet, capsule, granule, powder, pill, oral liquid, syrup or drop pill etc., is preferably granule.Warm water brews, and is easy to carry quick.
Pharmacology test is the result show, pharmaceutical composition of the present invention or health product are blood sugar lowering, control sugar effectively.Safety is taken in, side effect nontoxic to animal.
The usage of pharmaceutical composition of the present invention or health product and consumption: calculate by bag, 3 times on the oral one, each 1-2 bag also can be according to everyone concrete condition, and 2 times on the oral one, each 1-2 bag, every bag of content 2.5g.Take at once after the meal, the 30-50ml warm water brews.
The specific embodiment
Further describe by the following examples the present invention, it should be understood that these embodiment only are used for the purpose of illustration, never limit the scope of the invention.
Test material:
The used raw material of the present invention has Fructus Momordicae charantiae extract, olive fruits extract, Cortex Cinnamomi extract, guava fruit extract, Radix Et Rhizoma Fagopyri Tatarici extract, phylloxanthin, xylitol, astaxanthin and contains chromium yeast.
The used crude drug of the present invention all can be bought from Chinese medicine extract manufacturer and medical material manufacturer or distributor and obtain, the compound national standard of crude drug specification, and supplier's qualification, certificate are complete.
Embodiment 1
The preparation of powder
Take by weighing each component:: 260 parts of Fructus Momordicae charantiae extracts, 290 parts of Fructus Canrii Albi extracts, 230 parts of Cortex Cinnamomi extracts, 150 parts of guava extracts, 140 parts of Radix Et Rhizoma Fagopyri Tatarici extract, 20 parts of astaxanthins, 20 parts of phylloxanthins, contain 10 parts of chromium yeasts, 2500 parts of xylitol.
Mixing in the bag of packing into, and get final product; Every packed amount is 2.5g.
Embodiment 2
The preparation of granule
320 parts of Fructus Momordicae charantiae extracts, 400 parts of Fructus Canrii Albi extracts, 340 parts of Cortex Cinnamomi extracts, 200 parts of guava extracts, 200 parts of Radix Et Rhizoma Fagopyri Tatarici extract, 40 parts of astaxanthins, 25 parts of phylloxanthins, contain 13 parts of chromium yeasts, 2800 parts of xylitol.
With above-mentioned each component mix homogeneously, granulation, packing, and get final product, every packed amount is 2.5g.
Embodiment 3
The preparation of granule
Take by weighing each component: 380 parts of Fructus Momordicae charantiae extracts, 450 parts of Fructus Canrii Albi extracts, 380 parts of Cortex Cinnamomi extracts, 245 parts of guava extracts, 220 parts of Radix Et Rhizoma Fagopyri Tatarici extract, 50 parts of astaxanthins, 33 parts of phylloxanthins, contain 17 parts of chromium yeasts, 3000 parts of xylitol.
With above-mentioned each component mix homogeneously, granulation, packing, and get final product, every packed amount is 2.5g.
The pharmacology test of test example 3 pharmaceutical compositions of the present invention or health product function of blood sugar reduction.
1. materials and methods
1.1 tested material: adopt the prepared granule of the embodiment of the invention 3, be brown particle, the 2.5g/ bag.
1.2 laboratory animal
Secondary Kunming kind female mice, body weight 24-28g.
Provided the quality certification number by Military Medical Science Institute's Experimental Animal Center: SCXK-(army) 2001-0010051423.
1.3 experimental animal feeding environment
Feedstuff is provided by Military Medical Science Institute's Experimental Animal Center, the SPF level experimental animal room quality certification number: No. the 015th, the moving word of doctor, room temperature 21.0-22.3 ℃, relative humidity 50-62%.
1.4 dosage group selection and tested material give mode
Three dosage groups and a model control group.It is 0.625g/kg.BW (low dosage), 1.25g/kg.BW (middle dosage), 3.75g/kg.BW (high dose) that three dosage group dosage is respectively 5 times, 10 times, 30 times of human body recommended dose.Take by weighing respectively tested material 3.13g, 6.25g, 18.75g, be assigned to 100ml with distilled water, as the tested material of basic, normal, high three dosage groups, model control group gives the equivalent distilled water.Establish simultaneously two intact animal's groups, give respectively high dose tested material and distilled water.
Per os gives tested material, and the gavage amount is 20ml/kg.BW.
1.5 key instrument and reagent
Alloxan is available from U.S. Sigma company
Medisence 0ptium blood glucose meter is produced by U.S.'s Abbott Laboratories company limited.
Abbott Laboratories' (ANTU) blood sugar test paper is produced by U.S.'s Abbott Laboratories company limited.
1.6 test method
1.6.1 reduce the fasting glucose experiment
1.6.1.1 intact animal
Select 20 of Healthy female mices, fasting 5 hours is got tail blood and is surveyed blood glucose value.Be divided at random 2 groups according to blood sugar level, 10 every group, be respectively high dose group, Normal group.High dose group gives tested material, and the normal dose group gives distilled water, and gavage amount: 20ml/kg.BW gave after 30 days fasting 5 hours continuously, gets tail blood and surveys fasting blood sugar, relatively two treated animal blood glucose values.
1.6.1.2 hyperglycemia model animal
Select the Healthy female mice fasting of body weight 24-28g after 24 hours, the tail vein gives alloxan 40mg/kg (administered dose 10ml/kg.BW), and fasting is 5 hours after 6 days, gets tail blood and surveys blood glucose value.Blood glucose value is hyperglycemia model success animal at 10mmol/L～25mmol/L.Be divided at random 4 groups according to blood sugar level, 10 every group, be respectively model control group, low dose group, middle dosage group and high dose group.The dosage group gives the tested material of respective concentration, and model control group gives distilled water, and gavage amount: 20ml/kg.BW gave after 30 days fasting 5 hours continuously, gets tail blood and surveys fasting blood sugar, relatively each treated animal blood glucose value and blood glucose decline percentage rate.
Blood glucose value * 100% before blood glucose decline percentage rate=(blood glucose value after blood glucose value before the experiment-test)/experiment
1.6.2 anti-sugar amount experiment
Laboratory animal reduces fasting glucose experiment (hyperglycemia model animal).The dosage group gives the tested material of respective concentration, model control group gives distilled water, gavage amount: 20ml/kg.BW, gave continuously after 30 days fasting 5 hours, the dosage group gives the tested material of respective concentration again, model control group gives distilled water, gave glucose 2.0g/kg by mouth in 20 minutes, get the tail hematometry to glucose after 0,0.5,2 hour blood glucose value (0 hour blood glucose value can be used as fasting blood sugar), computation model matched group and tested material group to glucose after the variation of each time point Area under the curve of blood glucose, as anti-sugar amount observation index.
Area under the curve of blood glucose=0.25 * (0 hours blood glucose value+4 * 0.5 hours blood glucose values+3 * 2 hours blood glucose values)
All adopt SPSS11.5FORWINDOWS to carry out systematic analysis 1.7 respectively organize data.Wherein the intact animal adopts T-check, and animal pattern is adopted variance analysis and in twos check, and the person adopts data transaction such as heterogeneity of variance, still unevenly after the conversion then adopts rank test.
2, result
2.1 the impact on the laboratory animal body weight: (seeing Table 1,2)
Table 1 tested material is on the impact of normal Mouse Weight
Table 2 tested material is on the impact of hyperglycemia model Mouse Weight
By table 1,2 as seen, each dosage treated animal weightening finish is compared with corresponding matched group, and there are no significant for difference (P＞0.05).
2.2 the impact on the normal mouse fasting glucose
Table 3 tested material is on the impact (mmol/L) of normal mouse fasting glucose
By as seen from Table 3, per os gave the tested material of 3.75g/kg.BW (high dose) after 30 days, and the normal mouse fasting glucose is compared with Normal group, no significant difference (P＞0.05).
2.3 the impact on hyperglycemia model mice fasting glucose
Table 4 tested material is on hyperglycemia model mice fasting glucose and the percentile impact that descends
By as seen from Table 4, after 30 days, three dosage group fasting glucose all are lower than model control group with the tested material gavage hyperglycemia model mice of various dose, and each dosage group blood glucose decline percentage rate all is higher than model control group, and difference all has significance (P＜0.05).
2.4 the impact on the anti-sugar amount of diabetic mice
Table 5 tested material is on the impact of the anti-sugar amount of diabetic mice
By as seen from Table 5, after 30 days, each time point Area under the curve of blood glucose of high dose group is lower than model control group, and difference has significance (P＜0.05) with the tested material gavage hyperglycemia model mice of various dose.
3. brief summary
After 30 days, each dosage treated animal weightening finish is compared with corresponding matched group with the tested material gavage mice of various dose, and there are no significant for difference (P＞0.05); In the normal mouse, the fasting glucose of high dose group is compared with Normal group, no significant difference (P＞0.05); In the model mice, three dosage group fasting glucose all are lower than model control group, and each dosage group blood glucose decline percentage rate all is higher than model control group, and difference all has significance (P＜0.05); In the test of anti-sugar amount, each time point Area under the curve of blood glucose of high dose group is lower than model control group, and difference has significance (P＜0.05).Show that tested material has function of blood sugar reduction.
Prompting hypoglycemic drug of the present invention under this experiment condition makes up or health product have hypoglycemic effect.
The above only is preferred embodiment of the present invention, only is illustrative for the purpose of the present invention, and nonrestrictive.Those skilled in the art is understood, and can carry out many changes to it in the spirit and scope that claim of the present invention limits, revise, even equivalence, but all will fall within the scope of protection of the present invention.
Claims (8)
1. the pharmaceutical composition with hypoglycemic activity is characterized in that, comprises following component: Fructus Momordicae charantiae extract, Fructus Canrii Albi extract, Cortex Cinnamomi extract, guava extract, Radix Et Rhizoma Fagopyri Tatarici extract, astaxanthin, phylloxanthin, yeast chromium, xylitol.
2. according to the pharmaceutical composition of claim 1, it is characterized in that each component forms: Fructus Momordicae charantiae extract 260-520 part, Fructus Canrii Albi extract 290-600 part, Cortex Cinnamomi extract 230-540 part, guava extract 150-280 part, Radix Et Rhizoma Fagopyri Tatarici extract 140-310 part, astaxanthin 20-80 part, phylloxanthin 20-40 part, contain chromium yeast 10-25 part, xylitol 2500-3800 part.
3. according to the pharmaceutical composition of claim 2, it is characterized in that the weight portion of each component is: Fructus Momordicae charantiae extract 320-440 part, Fructus Canrii Albi extract 400-500 part, Cortex Cinnamomi extract 340-440 part, guava extract 200-250 part, Radix Et Rhizoma Fagopyri Tatarici extract 200-250 part, astaxanthin 40-65 part, phylloxanthin 25-35 part, contain chromium yeast 13-21 part, xylitol 2800-3300 part.
4. according to claim 3 pharmaceutical composition, it is characterized in that the weight portion of each component is: 380 parts of Fructus Momordicae charantiae extracts, 450 parts of Fructus Canrii Albi extracts, 380 parts of Cortex Cinnamomi extracts, 245 parts of guava extracts, 220 parts of Radix Et Rhizoma Fagopyri Tatarici extract, 50 parts of astaxanthins, 33 parts of phylloxanthins, contain 17 parts of chromium yeasts, 3000 parts of xylitol.
5. the described any pharmaceutical composition of claim 2-4 is characterized in that: after adding the needed adjuvant of preparations shaping or carrier, be prepared into any clinically acceptable suitable drugs preparation according to this area conventional formulation method.
6. according to the pharmaceutical composition of claim 5, it is characterized in that: described pharmaceutical preparation is tablet, capsule, granule, powder, pill, oral liquid or syrup.
7. according to the pharmaceutical composition of claim 5, it is characterized in that: described pharmaceutical preparation is granule.
8. the described any pharmaceutical composition of claim 1-5 has the purposes of the pharmaceutical composition of hypoglycemic activity in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105050968A CN102935116A (en) | 2012-12-03 | 2012-12-03 | Pharmaceutical compositions or health care product having blood sugar reduction effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105050968A CN102935116A (en) | 2012-12-03 | 2012-12-03 | Pharmaceutical compositions or health care product having blood sugar reduction effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102935116A true CN102935116A (en) | 2013-02-20 |
Family
ID=47694063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105050968A Pending CN102935116A (en) | 2012-12-03 | 2012-12-03 | Pharmaceutical compositions or health care product having blood sugar reduction effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102935116A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997119A (en) * | 2015-07-05 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | Astaxanthin health-care beverage with efficacy of reducing blood sugar |
| CN105192705A (en) * | 2015-10-28 | 2015-12-30 | 司双聚 | Nutritional health-care powder capable of conditioning blood sugar |
| CN105533687A (en) * | 2015-12-10 | 2016-05-04 | 张友兰 | Guava buccal tablets |
| CN106421741A (en) * | 2016-09-26 | 2017-02-22 | 南京中生生物科技有限公司 | Water-soluble olive leaf extract health-care product and preparation method thereof |
| CN107281262A (en) * | 2016-04-12 | 2017-10-24 | 汎宸企业股份有限公司 | Adjust the composition of blood glucose function |
| CN112566647A (en) * | 2018-08-31 | 2021-03-26 | 悠绿那股份有限公司 | Blood sugar level increase inhibitor, diabetes inhibitor and food composition |
| US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998650A (en) * | 2006-12-05 | 2007-07-18 | 高秀丽 | Use of cinnamonum cassia for treating diabetes, its products and preparing method |
| CN101143010A (en) * | 2006-09-15 | 2008-03-19 | 上海瑞品实业有限公司 | Special-purpose nutritive food for diabetes patient and its preparation method |
| US20090252796A1 (en) * | 2008-04-07 | 2009-10-08 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
| US20110159118A1 (en) * | 2004-12-08 | 2011-06-30 | Villoo Morawala Patell | Screening Method (Metabolite Grid) for Therapeutic Extracts and Molecules for Diabetes |
-
2012
- 2012-12-03 CN CN2012105050968A patent/CN102935116A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110159118A1 (en) * | 2004-12-08 | 2011-06-30 | Villoo Morawala Patell | Screening Method (Metabolite Grid) for Therapeutic Extracts and Molecules for Diabetes |
| CN101143010A (en) * | 2006-09-15 | 2008-03-19 | 上海瑞品实业有限公司 | Special-purpose nutritive food for diabetes patient and its preparation method |
| CN100998650A (en) * | 2006-12-05 | 2007-07-18 | 高秀丽 | Use of cinnamonum cassia for treating diabetes, its products and preparing method |
| US20090252796A1 (en) * | 2008-04-07 | 2009-10-08 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
Non-Patent Citations (3)
| Title |
|---|
| 《http://www.runkangpurui.com/ProductShow.asp?ID=122》 20120922 润康普瑞 安泰比特复合橄榄苦荞素-糖尿病人的必备品！ 1-2 1-8 , * |
| TPA DEVASAGAYAM，ET AL: "Free Radicals and Antioxidants in Human Health:Current Status and Future Prospects", 《JAPI》 * |
| 润康普瑞: "安泰比特复合橄榄苦荞素—糖尿病人的必备品！", 《HTTP://WWW.RUNKANGPURUI.COM/PRODUCTSHOW.ASP?ID=122》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997119A (en) * | 2015-07-05 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | Astaxanthin health-care beverage with efficacy of reducing blood sugar |
| CN105192705A (en) * | 2015-10-28 | 2015-12-30 | 司双聚 | Nutritional health-care powder capable of conditioning blood sugar |
| CN105533687A (en) * | 2015-12-10 | 2016-05-04 | 张友兰 | Guava buccal tablets |
| CN107281262A (en) * | 2016-04-12 | 2017-10-24 | 汎宸企业股份有限公司 | Adjust the composition of blood glucose function |
| CN106421741A (en) * | 2016-09-26 | 2017-02-22 | 南京中生生物科技有限公司 | Water-soluble olive leaf extract health-care product and preparation method thereof |
| US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
| CN112566647A (en) * | 2018-08-31 | 2021-03-26 | 悠绿那股份有限公司 | Blood sugar level increase inhibitor, diabetes inhibitor and food composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102935116A (en) | Pharmaceutical compositions or health care product having blood sugar reduction effect | |
| CN102845749B (en) | Health-care composition capable of improving sleep and aiding in improving memory | |
| CN102885309B (en) | Chloasma removing healthcare food composite and preparation method thereof | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN103110697B (en) | Pharmaceutical composition with hypoglycemic effect | |
| CN103734392A (en) | Fructus cannabis-black tartary buckwheat tea health beverage and preparation method thereof | |
| CN101695370B (en) | Health-care product for reducing blood sugar in assistant mode and preparation method thereof | |
| CN105725187A (en) | Blood sugar reducing composition and application in preparation of foods and health-care foods | |
| CN107319332A (en) | A kind of integration of drinking and medicinal herbs composition with hypoglycemic effect and preparation method thereof | |
| CN104256165A (en) | Functional feed for preventing and treating chronic swine plague and preparation method of functional feed | |
| CN106420955A (en) | Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| US20220047658A1 (en) | Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| CN102755568B (en) | Health-care product for assisting in decreasing blood sugar and preparation method thereof | |
| CN107281390A (en) | It is a kind of for Chinese medicine composition of health care and preparation method thereof | |
| KR20100104440A (en) | Natural tea composition prescribed based on patient's physical constitution | |
| CN105191859A (en) | Production method of low-cholesterol potassium-rich carotene-rich egg | |
| CN105031248A (en) | Health care product which contains Se-enriched cordyceps and is capable of assisting in blood sugar level regulation | |
| CN101352498B (en) | Formulation for improving thirst, polyphagia, hypodynamia and polyuria of diabetes patients | |
| CN1327879C (en) | Medicine for treating diabetes and its preparing method | |
| CN105663772B (en) | A kind of drug for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100083, Room 308, West three, building, group 30, Xueyuan Road, Beijing, Haidian District Applicant after: Beijing Recovery Biological Technology Co., Ltd. Address before: 100088 Beijing City, Haidian District Huayuan Road No. 13 Jardine Center office building room 318 Applicant before: Beijing Recovery Biological Technology Co., Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130220 |